Model | r2 | b | p Value |
Infliximab group | |||
MRI activity score: change from baseline to week 24 | |||
Baseline biomarker levels | |||
no parameters significantly associated | − | − | − |
Percentage change from baseline to week 2 in biomarker levels | 0.011 | ||
IL-6 | 0.053 | <0.001 | |
Percentage change from baseline to week 24 in biomarker levels | 0.042 | ||
CRP | 0.009 | 0.009 | |
BASDAI: change from baseline to week 24 | |||
Baseline biomarker levels | 0.043 | ||
CRP | −0.196 | 0.005 | |
Percentage change from baseline to week 2 in biomarker levels | 0.099 | ||
IL-6 | 0.021 | <0.001 | |
Percentage change from baseline to week 24 in biomarker levels | 0.113 | ||
VEGF | 0.005 | 0.029 | |
CRP | 0.005 | 0.005 | |
Placebo group | |||
No biomarker levels at baseline or changes from baseline to week 2 or 24 were significantly associated with changes in MRI activity score or BASDAI at week 24 |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; IL-6, interleukin-6; MRI, magnetic resonance imaging; VEGF, vascular endothelial growth factor.